“Getting started” here means getting informed, not beginning a practice. This cluster is an orientation to the topic and the open questions — what a microdose is, what the evidence does and does not support, what the risks are, and what to ask — so that any decision you reach is an informed one, including the decision not to proceed. [1] Systematic review The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field doi:10.1016/j.neubiorev.2022.104706 It is not a protocol, a starting dose, a schedule, a sourcing guide, or legal advice. The most rigorous trials find reported benefits are largely explained by expectation rather than the drug, [2] Clinical trial Self-blinding citizen science to explore psychedelic microdosing doi:10.7554/eLife.62878 and the field as a whole remains short on controlled evidence. [3] Peer-reviewed Microdosing psychedelics: More questions than answers? An overview and suggestions for future research doi:10.1177/0269881119857204 Read this to understand the topic; route health questions to Safety, legality to Legal Status, and mechanism to How It Works. [4] Peer-reviewed Psychedelics doi:10.1124/pr.115.011478
Education-only orientation. This is not medical, dosing, sourcing, or legal advice. Nothing here tells you to begin, how to begin, or where to obtain anything.
A map of what to understand, not instructions to act. The reader who finishes informed and decides “not for me” or “not now” has used this cluster correctly.
Not an instruction guide. This cluster gives no dose, protocol, schedule, sourcing, legal clearance, or medical advice — only the concepts, risks, evidence limits, and questions to understand before any decision, including the decision not to proceed.
What this cluster is — and what it deliberately is not
There is a predictable trap in any “getting started” guide on a drug topic: it quietly becomes an on-ramp. A starting dose appears, a schedule follows, and orientation has turned into instruction. This cluster refuses that turn on purpose.
What it offers is a map of what to understand before forming any view: the prerequisite concepts, the questions worth asking, the risk landscape, the gap between hype and evidence, and the reading order through the rest of the library. What it withholds, everywhere, is the instructional layer — no first dose, no amounts, no schedule to begin on, no sourcing, cultivation, or preparation. Those are not omissions to be filled in elsewhere on the site; they are out of scope by design.
The reason is simple. An informed decision and a how-to are different products. Confusing them is how people end up acting before they understand, which is the opposite of harm reduction. [1] Systematic review The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field doi:10.1016/j.neubiorev.2022.104706
The four distinctions to carry throughout
Almost every misunderstanding in this field comes from collapsing one of four distinctions. Keep them apart and the topic becomes legible.
| Distinction | What it means | Common error it prevents |
|---|---|---|
| Mechanism ≠ result | A plausible biological pathway is not proof of a benefit | ”It binds 5-HT2A, so it must work” |
| Full-dose ≠ microdose | Findings from full psychedelic doses do not transfer to sub-perceptual doses | Importing therapy-trial results into microdosing |
| Reports ≠ outcomes | Self-reported improvement is data about reports, not a measured effect | ”Thousands say it helped, so it works” |
| Plausibility ≠ demonstrated efficacy | Something can be biologically plausible and still unproven | Treating “could work” as “does work” |
The controlled evidence underlines why these matter: the most rigorous microdosing study to date, a large self-blinding trial, found that the benefits participants reported were largely matched by placebo — expectation, not the compound, did most of the work. [2] Clinical trial Self-blinding citizen science to explore psychedelic microdosing doi:10.7554/eLife.62878
Where each question goes
This cluster is a hub. It does not try to answer health, legal, or mechanism questions itself; it routes them to the part of the library built to answer them.
- What a microdose even is, and how the field is studied → Foundations.
- How the compound works in the body → How It Works, including what the mechanism does and doesn’t show.
- Risk, contraindications, vulnerability → Safety.
- Medications and combinations → Interactions.
- What is lawful and how laws are categorised → Legal Status.
- What studies actually used as schedules → Protocols, described as referenced research, never as your starting point.
- What conditions the research examines → Use Cases.
How to use the rest of this cluster
Read it as a sequence. Understand the prerequisite concepts, then learn the questions to ask, then meet the risk landscape first, then calibrate expectations against the evidence, then learn to evaluate what you read, then clear the common misconceptions — and finish with the research-first starting point that ties it together. At no stage does the path point at a dose.
Reading is educational, not self-clearance
A well-informed decision can be yes, no, not now, or only after clinician review — and this cluster exists to make that decision rest on evidence rather than hype, not to move anyone toward use. Reading educational material improves understanding, but it cannot evaluate your medical history, psychiatric vulnerability, medication interactions, or legal exposure. Education is useful precisely because it reveals the limits of self-clearance: the better-informed reader often understands why the answer may still be no. The beginner’s question is usually “How do I start?” The more useful first question is “What would I need to understand before this decision could be informed?” — and that shift changes the entire conversation.
- Getting started = getting informed
- The deliverable is understanding and good questions, not a beginner protocol. [1] Systematic review The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field doi:10.1016/j.neubiorev.2022.104706
- Orientation, not instruction
- No starting dose, schedule, sourcing, or how-to appears here or elsewhere on the site.
- Expectation does the heavy lifting
- The strongest trial attributes most reported benefit to expectancy, not the drug. [2] Clinical trial Self-blinding citizen science to explore psychedelic microdosing doi:10.7554/eLife.62878
- A field still thin on evidence
- Overviews describe more open questions than settled answers. [3] Peer-reviewed Microdosing psychedelics: More questions than answers? An overview and suggestions for future research doi:10.1177/0269881119857204
Frequently asked questions
Does getting started mean this site will teach me how to begin microdosing?
No. This cluster is deliberately an orientation to understanding the topic, not an instruction manual for beginning. It does not give starting doses, schedules, sourcing, or a how-to. Getting started here means getting informed: learning what a microdose is, what the evidence does and does not show, what the risks are, and what questions to ask, so that any decision you reach is an informed one. Concluding that microdosing is not for you, or not now, is using this material exactly as intended.
Where should I begin reading?
Begin with what a microdose actually is, then how the field is studied and why it is hard to study, then the safety landscape, then how to read claims critically. This overview links each step in order. The aim is to build the background needed to evaluate the topic rather than to walk you toward a first dose. The capstone article lays out the full recommended reading order through the library.
Is microdosing proven to work?
No. The controlled evidence remains limited, and the most rigorous studies to date — including a large self-blinding trial — found that improvements people report are largely explained by expectation rather than by the drug. Systematic reviews describe a field still short on high-quality controlled data. Reports of benefit are real as reports, but a report is not the same as a demonstrated outcome, and plausibility is not demonstrated efficacy.
Does this site tell me where to get psilocybin or whether it is legal where I live?
No. Sourcing, acquisition, cultivation, and preparation are out of scope everywhere on this site. Questions about what is lawful are routed to the legal-status material, which explains how laws are categorised rather than advising on your situation, and supply questions are routed to the access material. For your specific legal position, consult a qualified attorney licensed where you live.
What is the single most important idea to carry into the rest of the library?
Hold four distinctions apart: a mechanism is not a result, a full dose is not a microdose, a report is not an outcome, and plausibility is not demonstrated efficacy. Almost every confusion in this area comes from collapsing one of these. If you keep them separate as you read, marketing claims, anecdotes, and study findings each fall into their proper place, and you can judge the topic on the evidence rather than on enthusiasm.